Novo Nordisk offers diabetes drug Ozempic for less than half the price for cash-paying U.S. patients
Novo Nordisk said it now offers cash-paying U.S. patients its blockbuster diabetes treatment Ozempic for less than half its monthly list price through multiple platforms. Patients can pay $499 in cash per month for three dose sizes of Ozempic through the drug's official website, Novo Nordisk's patient assistance program, the company's recently launched direct-to-consumer online pharmacy and drug savings company GoodRx, among other platforms.
Novo Nordisk Stock Is Jumping. Weight-Loss Drug Wegovy Has Something to Do With It.
Novo Nordisk makes the wildly popular GLP-1 drug semaglutide which it sells under the brand name Wegovy for weight-loss and Ozempic for diabetes.
Novo Nordisk shares are rising. The FDA approves another use for Wegovy.
Novo Nordisk shares were climbing Monday after the Food and Drug Administration approved the popular weight-loss drug Wegovy to treat a form of liver disease.
Shares in Novo Nordisk rise after Wegovy gets US nod for liver disease treatment
Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver condition, positive news for the drugmaker that lost more than one-third of its market value in recent weeks.
It's Time To Be All-In On Novo Nordisk
Novo Nordisk's current valuation is highly attractive, offering a compelling risk-reward for turnaround investors despite recent stock declines and margin pressures. GLP-1 therapies, especially Ozempic and Wegovy, are driving robust growth, but competition from Eli Lilly and compounded versions present near-term headwinds. Strong fundamentals include industry-leading margins, high ROE, consistent share buybacks, and a fast-growing dividend yield, supporting long-term shareholder value.
Novo Nordisk launches weight-loss drug Wegovy in South Africa
Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa on Thursday, marking its debut in Africa and stepping up competition with Eli Lilly's Mounjaro launched in the country eight months earlier.
A Cure For Novo Nordisk
NVO has sector headwinds and product growth concerns. These problems don't have an easy solution and the market has administered its own cure - a 70% drop. The bad news should be mostly priced in. $47.50 is a strong technical support; I expect stabilization and a gradual recovery from this level.
Novo Nordisk Rises 6% So Far in August: How to Play the Stock
NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's advancing pipeline.
Novo Nordisk: The Falling Knife That Keeps Giving
Novo Nordisk remains a buy despite share price weakness, as strong earnings and robust market share in diabetes and obesity care drive growth. The company's pipeline is rich, with late-stage R&D in obesity, cardiovascular, and rare diseases, including promising drugs like oral semaglutide and Mim8. Shareholder returns are supported by strong free cash flow, double-digit profit growth, and disciplined capital expenditures for future expansion.
Here's Why Novo Nordisk (NVO) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Novo Nordisk A/S (NVO) is Attracting Investor Attention: Here is What You Should Know
Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Novo Nordisk: Watching Value Investors Buy The Dip Hurts My Eyes
I was right with my Strong Sell rating for Novo Nordisk A/S and the main pillar of my bear case: market share erosion in weight loss treatment. FY 2025 guidance cuts—sales 8–14% CER and operating profit 10–16%—are driven by softer U.S. Wegovy/Ozempic and GLP-1 trends. Furthermore, Wegovy is lagging behind tirzepatide in market share. Given revised guidance and flat growth expectations, I expect the stock to consolidate around $50 for the back half of the year. Therefore, my Hold rating.
